 |
52 Diseases |  |
108 Trials |
|
108 Trials |  |
1268 News |  |
| 12345678910111213...2122» |
- | mivavotinib (CB-659) / Calithera, Rituxan (rituximab) / Roche
Trial completion: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jun 18, 2025
P1, N=12, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed
- | Kepivance (palifermin) / SOBI, Amgen
Trial completion, Trial completion date: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Jun 5, 2025
P1/2, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Mar 2025
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: RITUXERA: Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jun 2, 2025
P4, N=134, Recruiting, Sponsor: Universitaire Ziekenhuizen KU Leuven
Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Mar 2025 Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Window-2: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - May 30, 2025
P2, N=51, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027 Trial completion date: May 2025 --> Mar 2027 | Trial primary completion date: May 2025 --> Mar 2027
- | Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - May 30, 2025
P3, N=244, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2025 --> Mar 2027 | Trial primary completion date: May 2025 --> Mar 2027 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - May 30, 2025
P1, N=54, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Rituxan (rituximab) / Roche
Enrollment closed, Trial completion date: REDUCE-PMR-1: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed (clinicaltrials.gov) - May 30, 2025
P3, N=114, Active, not recruiting, Sponsor: Sint Maartenskliniek
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Apr 2026
- | Venclexta (venetoclax) / Roche, AbbVie, emilumenib succinate (DS-1594) / Daiichi Sankyo
Trial termination: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 23, 2025
P1/2, N=17, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Apr 2026 Completed --> Terminated; supporting/funding source decided to de-prioritize and stop development of DS-1594
- ||| Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: REDUCE-PMR-2: Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse (clinicaltrials.gov) - May 16, 2025
P3, N=174, Recruiting, Sponsor: Sint Maartenskliniek
Completed --> Terminated; supporting/funding source decided to de-prioritize and stop development of DS-1594 Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
- | Monjuvi (tafasitamab-cxix) / Incyte, Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
Enrollment closed: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study (clinicaltrials.gov) - May 16, 2025
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027 Recruiting --> Active, not recruiting
- |||| zilovertamab vedotin (MK-2140) / Merck (MSD)
Trial primary completion date: waveLINE-010: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (clinicaltrials.gov) - May 14, 2025
P3, N=1046, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2032 --> Jul 2029
- | Enrollment change, Trial termination: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (clinicaltrials.gov) - May 14, 2025
P1, N=17, Terminated, Sponsor: Mayo Clinic
Trial primary completion date: Mar 2032 --> Jul 2029 N=39 --> 17 | Suspended --> Terminated; funding - sponsor filing Chapter 11 bankruptcy
- | Ojemda (tovorafenib) / Day One Biopharma, Rituxan (rituximab) / Roche
New P1/2 trial: Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment (clinicaltrials.gov) - May 12, 2025
P1/2, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Personalized NK Cell Therapy in CBT (clinicaltrials.gov) - May 9, 2025
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=39 --> 17 | Suspended --> Terminated; funding - sponsor filing Chapter 11 bankruptcy Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2025 --> May 2027
- | Venclexta (venetoclax) / Roche, AbbVie, Iclusig (ponatinib) / Takeda
Trial termination: NCI-2018-01100: Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia (clinicaltrials.gov) - May 8, 2025
P1/2, N=9, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2025 --> May 2027 | Trial primary completion date: May 2025 --> May 2027 Completed --> Terminated; The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial completion date, Trial primary completion date: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - May 5, 2025
P3, N=435, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Terminated; The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Jun 2026 | Trial primary completion date: Dec 2027 --> Jun 2026
- | Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov) - May 2, 2025
P2, N=8, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Jun 2026 | Trial primary completion date: Dec 2027 --> Jun 2026 Recruiting --> Active, not recruiting | N=49 --> 8 | Trial completion date: Nov 2026 --> Jun 2025 | Trial primary completion date: Nov 2025 --> Jun 2025
- |||| zilovertamab vedotin (MK-2140) / Merck (MSD)
Enrollment open: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (clinicaltrials.gov) - May 1, 2025
P2, N=594, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting | N=49 --> 8 | Trial completion date: Nov 2026 --> Jun 2025 | Trial primary completion date: Nov 2025 --> Jun 2025 Not yet recruiting --> Recruiting
- | Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion date: NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 26, 2025
P1/2, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial completion date: Mar 2025 --> Feb 2026
- || sonrotoclax (BGB-11417) / BeiGene, Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Enrollment open: SONIC: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 26, 2025
P2, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Trial completion date: Mar 2025 --> Feb 2026 Not yet recruiting --> Recruiting
- | evorpacept (ALX148) / ALX Oncology, Rituxan (rituximab) / Roche
Enrollment closed: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 25, 2025
P1/2, N=47, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Ninlaro (ixazomib) / Takeda, Rituxan (rituximab) / Roche
Trial completion date, Trial termination: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 21, 2025
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Jul 2025 --> Apr 2025 | Active, not recruiting --> Terminated; Administratively Complete 75%<Participants
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 15, 2025
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2025 --> Apr 2025 | Active, not recruiting --> Terminated; Administratively Complete 75%<Participants Trial completion date: Mar 2025 --> Mar 2026
- | Ninlaro (ixazomib) / Takeda, Rituxan (rituximab) / Roche
Trial completion date: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 7, 2025
P2, N=3, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2025 --> Mar 2026 Trial completion date: Dec 2025 --> Jul 2025
- | Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (clinicaltrials.gov) - Apr 7, 2025
P2, N=36, Active, not recruiting, Sponsor: Christian Buske
Trial completion date: Dec 2025 --> Jul 2025 Trial completion date: Dec 2029 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2027
- | Opdivo (nivolumab) / BMS
Trial completion date: NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 2, 2025
P2, N=30, Active, not recruiting, Sponsor: David Bond, MD
Trial completion date: Dec 2029 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2027 Trial completion date: Dec 2024 --> Dec 2025
- | Elzonris (tagraxofusp-erzs) / Menarini
Trial completion date: Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 1, 2025
P1/2, N=4, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2024 --> Dec 2025 Trial completion date: Jul 2025 --> Jul 2024
- | Epkinly (epcoritamab-bysp) / Genmab, AbbVie
New P2 trial: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Apr 1, 2025
P2, N=25, Not yet recruiting, Sponsor: University of California, Davis
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Rituxan (rituximab) / Roche
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab and between biosimilars in connective tissue diseases and vasculitis (Poster Area) - Mar 30, 2025 - Abstract #EULAR2025EULAR_2783;
Trial completion date: Jul 2025 --> Jul 2024 Furthermore, between 2021-2023, patients on Truxima
- | Trial completion, Trial completion date, Trial primary completion date: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 26, 2025
P1, N=16, Completed, Sponsor: City of Hope Medical Center
Furthermore, between 2021-2023, patients on Truxima Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Dec 2024 --> Jun 2024
- Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Ruxience (rituximab-pvvr) / Pfizer, Rituxan (rituximab) / Roche
Cost-Efficiency Modeling of Conversion to Biosimilar Rituximab-pvvr in Diffuse Large B-Cell Lymphoma in Medicare () - Mar 24, 2025 - Abstract #ISPOR2025ISPOR_1968;
These savings represent 33% and 66% reductions in cost vs. originator-based treatment, respectively, and exceed savings from alternative biosimilars rituximab-abbs or -arrx. We found that R-CHOP with rituximab-pvvr can achieve substantial cost savings relative to originator-based treatment, allowing reinvestment to treat a substantial number of additional patients with DLBCL, or fund other costs of care in Medicare, on a budget-neutral basis.
- ||||| zilovertamab vedotin (MK-2140) / Merck (MSD)
New P2 trial: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) (clinicaltrials.gov) - Mar 24, 2025
P2, N=594, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
Trial completion date, Trial primary completion date: Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma (clinicaltrials.gov) - Mar 20, 2025
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
We found that R-CHOP with rituximab-pvvr can achieve substantial cost savings relative to originator-based treatment, allowing reinvestment to treat a substantial number of additional patients with DLBCL, or fund other costs of care in Medicare, on a budget-neutral basis. Trial completion date: Mar 2025 --> Mar 2028 | Trial primary completion date: Mar 2025 --> Mar 2028
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Trial completion date: Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 20, 2025
P1/2, N=83, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2025 --> Mar 2028 | Trial primary completion date: Mar 2025 --> Mar 2028 Trial completion date: Mar 2025 --> Mar 2026
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Mar 13, 2025
P3, N=529, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2025 --> Mar 2026 Trial completion date: Dec 2024 --> Jan 2026
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: ALLIANCE A041202: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 13, 2025
P3, N=547, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2024 --> Jan 2026 Trial completion date: Jan 2025 --> Jan 2026
- | Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
Trial primary completion date: NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Mar 6, 2025
P1, N=20, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial completion date: Jan 2025 --> Jan 2026 Trial primary completion date: Dec 2025 --> Dec 2026
- | Keytruda (pembrolizumab) / Merck (MSD), Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Pembrolizumab, Ibrutinib and Rituximab in PCNSL (clinicaltrials.gov) - Mar 5, 2025
P1/2, N=37, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2025 --> Dec 2026 Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Dec 2025
- |||| sonrotoclax (BGB-11417) / BeiGene, Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
New P2 trial: BRAZAN Trial in Frontline MCL (clinicaltrials.gov) - Mar 3, 2025
P2, N=60, Not yet recruiting, Sponsor: Christine Ryan
- | Brukinsa (zanubrutinib) / BeiGene
Trial completion date, Trial primary completion date: Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 26, 2025
P1, N=24, Recruiting, Sponsor: Yazeed Sawalha
Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Feb 2025 --> Dec 2025 Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025
- | Rituxan (rituximab) / Roche
Journal: Increasing Biosimilar Uptake in Rheumatology Clinics Within a Large Academic Medical Center. (Pubmed Central) - Feb 25, 2025
Biosimilar use among rheumatology providers in an academic setting can be increased through multimodal interventions including education and EHR modifications. This change has the potential for large cost savings.
- || sonrotoclax (BGB-11417) / BeiGene, Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
New P2 trial: SONIC: Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 21, 2025
P2, N=20, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Center
- | Monjuvi (tafasitamab-cxix) / Incyte, Rituxan (rituximab) / Roche
Trial primary completion date: Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder (clinicaltrials.gov) - Feb 21, 2025
P2, N=28, Recruiting, Sponsor: Timothy Voorhees
This change has the potential for large cost savings. Trial primary completion date: Dec 2024 --> Dec 2025
- | Mavenclad (cladribine) / EMD Serono
Enrollment closed, Trial completion date, Trial primary completion date: TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - Feb 18, 2025
P=N/A, N=900, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Dec 2024 --> Dec 2025 Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
- | Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Trial completion date: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 18, 2025
P2, N=41, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026 Trial completion date: Dec 2024 --> Jul 2025
- | Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial primary completion date: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Feb 13, 2025
P3, N=244, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2024 --> Jul 2025 Trial primary completion date: Sep 2027 --> Dec 2027 | Trial completion date: Sep 2027 --> Dec 2027
- | mivavotinib (CB-659) / Calithera, Rituxan (rituximab) / Roche
Enrollment closed, Trial completion date: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 11, 2025
P1, N=12, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Sep 2027 --> Dec 2027 | Trial completion date: Sep 2027 --> Dec 2027 Completed --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2028
- | Iclusig (ponatinib) / Takeda, Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: NCI-2018-01186: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 8, 2025
P2, N=22, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2028 Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2027
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Feb 4, 2025
P2, N=44, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Feb 2025 --> Feb 2027 Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
- | Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
Enrollment closed: Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Feb 4, 2025
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027 Recruiting --> Active, not recruiting